title: Characteristics of 10-year survivors of high-grade serous ovarian carcinoma.
abstract: OBJECTIVE
  High-grade serous carcinoma (HGSC) generally presents at an advanced stage with poor long-term (LT) survival. Here we describe clinical features found in women surviving HGSC for ten or more years.
  
  
  METHODS
  A multi-center research consortium was established between five participating academic centers. Patient selection criteria included high-grade serous ovarian, fallopian tube, or peritoneal carcinoma with at least ten years of follow up. Non-serous, borderline tumors and low-grade serous subtypes were excluded.
  
  
  RESULTS
  The 203 identified LT ten-year survivors with HGSC were diagnosed at a median age of 57years (range 37-84years). The majority of patients had stage IIIC (72.4%) disease at presentation. Of those who underwent primary cytoreductive surgery, optimal cytoreduction was achieved in 143 (85.6%) patients. After a median follow up of 144months, 88 (46.8%) patients did not develop recurrent disease after initial treatment. Unexpected findings from this survey of LT survivors includes 14% of patients having had suboptimal cytoreduction, 11% of patients having an initial platinum free interval of <12months, and nearly 53% of patients having recurrent disease, yet still surviving more than ten years after diagnosis.
  
  
  CONCLUSIONS
  LT survivors of HGSC of the ovary generally have favorable clinical features including optimal surgical cytoreduction and primary platinum sensitive disease. The majority of patients will develop recurrent disease, however many remained disease free for more than 10years. Future work will compare the clinical features of this unusual cohort of LT survivors with the characteristics of HGSC patients having less favorable outcomes.
authors.affiliation: Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, NY, New York, United States.
authors.forename: Fanny
authors.initials: F
authors.lastname: Dao
authors.affiliation: Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, NY, New York, United States.
authors.forename: Brooke A
authors.initials: BA
authors.lastname: Schlappe
authors.affiliation: Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, NY, New York, United States.
authors.forename: Jill
authors.initials: J
authors.lastname: Tseng
authors.affiliation: Women's Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
authors.forename: Jenny
authors.initials: J
authors.lastname: Lester
authors.affiliation: Departments of Gynecologic Oncology, Cancer Biology, Center for RNA Interference and Noncoding RNA, University of Texas, M.D. Anderson Cancer Center, United States.
authors.forename: Alpa M
authors.initials: AM
authors.lastname: Nick
authors.affiliation: Departments of Psychological and Brain Sciences, Obstetrics and Gynecology and Urology, Holden Comprehensive Cancer Center, University of Iowa, United States.
authors.forename: Susan K
authors.initials: SK
authors.lastname: Lutgendorf
authors.affiliation: Stephenson Oklahoma Cancer Center, University of Oklahoma, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Oklahoma City, OK, United States.
authors.forename: Scott
authors.initials: S
authors.lastname: McMeekin
authors.affiliation: Departments of Gynecologic Oncology, Cancer Biology, Center for RNA Interference and Noncoding RNA, University of Texas, M.D. Anderson Cancer Center, United States.
authors.forename: Robert L
authors.initials: RL
authors.lastname: Coleman
authors.affiliation: Stephenson Oklahoma Cancer Center, University of Oklahoma, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Oklahoma City, OK, United States.
authors.forename: Kathleen N
authors.initials: KN
authors.lastname: Moore
authors.affiliation: Women's Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
authors.forename: Beth Y
authors.initials: BY
authors.lastname: Karlan
authors.affiliation: Departments of Gynecologic Oncology, Cancer Biology, Center for RNA Interference and Noncoding RNA, University of Texas, M.D. Anderson Cancer Center, United States.
authors.forename: Anil K
authors.initials: AK
authors.lastname: Sood
authors.affiliation: Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, NY, New York, United States. Electronic address: levine2@mskcc.org.
authors.forename: Douglas A
authors.initials: DA
authors.lastname: Levine
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018284:Cystadenocarcinoma, Serous / Q000235:genetics / Q000401:mortality* / Q000473:pathology*; D005260:Female; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D018095:Germ-Line Mutation; D006801:Humans; D008875:Middle Aged; D060787:Neoplasm Grading; D010051:Ovarian Neoplasms / Q000235:genetics / Q000401:mortality* / Q000473:pathology* / Q000628:therapy; D010865:Pilot Projects; D017741:Survivors / Q000706:statistics & numerical data*; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology
keywords: Long-term survival; Neoadjuvant chemotherapy; Outcome; Ovarian cancer; Surgical cytoreduction; Survival